Medpace Holdings, Inc. (MEDP): Capital Expenditures
$31.36M
Year ended 2025-12-31
$45.97M
Trailing 12 months to 2026-06-30
-5.3%
3-year compound annual growth
0.0%
5-year compound annual growth
+17.1%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $31.36M | -14.2% | 2026-02-10, From 2025-01-01 |
| 2024-12-31 | $36.55M | -0.3% | 2026-02-10, From 2024-01-01 |
| 2023-12-31 | $36.65M | -0.6% | 2026-02-10, From 2023-01-01 |
| 2022-12-31 | $36.88M | +30.4% | 2025-02-11, From 2022-01-01 |
| 2021-12-31 | $28.27M | -9.8% | 2024-02-13, From 2021-01-01 |
| 2020-12-31 | $31.34M | +75.0% | 2023-02-14, From 2020-01-01 |
| 2019-12-31 | $17.91M | +11.8% | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | $16.02M | +36.7% | 2021-02-16, From 2018-01-01 |
| 2017-12-31 | $11.72M | -13.4% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $13.54M | +109.4% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $6.46M | n/a | 2018-02-27, From 2015-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $31.36M | -14.2% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $219.15M | -5.9% |
| Icon PLC (ICLR) | 2025-12-31 | $174.21M | +3.7% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $603.00M | +0.2% |
| NRC Health (NRC) | 2025-12-31 | $10.71M | -30.7% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $1.77M | +7.1% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $565.0K | -69.9% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $62.0K | n/a |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | $60.6K | -23.4% |
Compare MEDP, CRL, ICLR, IQV side by side · Screen every company in Services-Commercial Physical & Biological Research ↗